The opioid-induced constipation treatment market across the six major countries of the US, Germany, France, Italy, Spain and the UK will increase from an estimated $66.7 million in 2014 to $652.4 million by 2019, representing a rapid CAGR of 57.8%. The rising number of opioid-induced constipation sufferers is largely down to overall population increase and the continued use of opioids in the treatment of chronic non-cancer pain, which is driving impressive market growth. The introduction of novel targeted oral therapies for opioid-induced constipation, such as peripherally-acting mu-opioid receptor antagonists (PAMORAs), will be a major driver of market growth during the forecast period.

GlobalData’s OpportunityAnalyzer: Opioid-Induced Constipation – Opportunity Analysis and Forecasts to 2019 report provides analysis of the current and future market competition in the opioid-induced constipation (OIC) therapeutics space across the six major countries of the US, Germany, France, Italy, Spain and the UK, featuring annualized market data from 2014 and forecast to 2019. It discusses market characterization, unmet needs, clinical trial mapping and implications for the OIC therapeutics arena.

Single User Price: $9,495